OvaScience, Inc., a life sciences company, is engaged in the discovery, development, and commercialization of new treatments for infertility. The company's patented technology is based on the discovery of egg precursor cells (EggPCs), which are found in the ovaries. It is developing various fertility treatment options designed to enhance egg quality and in vitro fertilization (IVF) comprising AUGMENT to improve egg quality and increase the success of IVF by transferring mitochondria from a woman's EggPCs to her mature egg during IVF; OvaPrime for boosting a woman's egg reserve by transferring the EggPCs from the outer layer of her ovary back into the ovary prior to IVF; OvaTure to create mature fertilizable eggs from a woman's own EggPCs without the need for hormone injections; and OvaXon to develop an approach to the prevention of genetic disease and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative bacteria. The company is conducting a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and a second Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to-oral step-down therapy. It is also developing TP-271, a preclinical compound for respiratory diseases caused by bacterial biothreat pathogens; and preclinical Gram-negative program for multidrug-resistant Gram-negative infections. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Optical Cable Corporation, together with its subsidiaries, manufactures and sells fiber optic and copper data communications cabling and connectivity solutions for the enterprise market in the United States and internationally. The company markets and sells various copper datacom cables, including unshielded and shielded twisted pair. It also offers fiber optic connectivity products, including fiber optic wall mounts, cabinet mount and rack mount enclosures, pre-terminated fiber optic enclosures, fiber optic connectors, splice trays, fiber optic jumpers, plug and play cassette modules, pre-terminated fiber optic cable assemblies, adapters, and accessories. In addition, the company provides copper connectivity products comprising category compliant patch panels, jacks, plugs, patch cords, faceplates, surface mounted boxes, distribution and multi-media boxes, copper rack mount and wall mount enclosures, cable assemblies, cable organizers, and other wiring products for datacenter, telecommunications closet, equipment room, and workstation applications. Further, it offers network, data storage, and telecommunications management systems, such as data cabinets, wall-mount enclosures, cable management systems, and open frame relay racks for commercial and residential use; various enclosures, modules, and modular outlets for single dwelling and multiple dwelling residential uses; and cellular distribution system, a distributed antenna system for in-building enhancement of wireless communications signals. Additionally, the company provides applied interconnect systems, which include specialty fiber optic connectors and connectivity components, ruggedized copper datacom connectors, and related systems and solutions for military and harsh environment applications. The company sells its products to distributors, original equipment manufacturers, value-added resellers, and end-users. Optical Cable Corporation was founded in 1983 and is headquartered in Roanoke, Virginia.
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic obstructive pulmonary disease and other chronic respiratory conditions. It offers Inogen One systems, which are portable devices that concentrate the air around them to offer a single source of supplemental oxygen; and related accessories to patients, insurance carriers, home healthcare providers, and distributors. The company sells its products in the United States and internationally. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Office Depot, Inc., together with its subsidiaries, supplies office products and services. The company's North American Retail division sells an assortment of merchandise, including office supplies, technology products and solutions, business machines and related supplies, facilities products, and office furniture under various brands through its chain of office supply stores. Its North American Business Solutions division sells branded office supplies, technology products, cleaning and breakroom supplies, office furniture, services, and other solutions, as well as copy and print services to small, medium, and large-sized businesses through a sales force, catalogs, telesales, Internet sites, and limited store locations. The company's International division sells office products and services through direct mail catalogs, contract sales forces, Internet sites, and retail stores using company-owned operations, joint ventures, licensing and franchise agreements, alliances, and other arrangements. This division also participates under licensing and merchandise arrangements in South Korea, Israel, the Dominican Republic, and the Middle East. It offers its products under various labels, including Office Depot, OfficeMax, Viking Office Products, Foray, Ativa, Grand & Toy, TUL, and DiVOGA. As of February 25, 2014, the company operated 2,200 retail stores in 57 countries. Office Depot, Inc. was founded in 1986 and is headquartered in Boca Raton, Florida.
Synergetics USA, Inc., a medical device company, provides precision surgical devices, surgical equipment, and consumables primarily for the ophthalmology and neurosurgery markets in the United States and internationally. The company's product lines focuses upon precision engineered disposable and reusable devices, surgical equipment, procedural kits, and the delivery of various energy modalities, including laser energy, ultrasonic energy, radio frequency energy for electro surgery and lesion generation, and visible light energy for illumination. It offers approximately 1,000 separate catalogue items in the vitreoretinal surgical market, including vitrectomy system under the VersaVIT 2.0 brand; procedural packs under VersaPACK and Core Essentials brands; fiberoptic endoilluminators and endolaser probes; various disposable and reusable devices designed for intraocular manipulation of tissues; illumination equipment under the Photon brand; laser equipment for the United States market under Ellex's Solitaire brand; Volk's line of ophthalmic lenses; Labtician's scleral buckles; and other miscellaneous products. The company sells its products directly, as well as through distributors and independent sales representatives to end-users at hospitals, ambulatory surgery centers, and surgeon offices. Synergetics USA, Inc. is headquartered in O'Fallon, Missouri.
Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company's products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men's and women's health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions. The company has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Boehringer Ingelheim International GmbH to research, develop, and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through its proprietary XmAb technology platform. The company's lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor under Phase Ib clinical trial initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate that is in Phase II clinical trials for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Oracle Corporation develops, manufactures, markets, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide. It provides software and hardware systems, and related services to manage their cloud-based or on-premise IT environments, as well as to deploy cloud software-as-a-service, platform-as-a-service, and infrastructure-as-a-service. The company offers software for mobile computing; database and middleware software that runs and manages business applications for midsize businesses and large enterprises; and Java, a software development language. It also provides applications software, such as human capital and talent management, customer experience and customer relationship management, financial management and governance, risk and compliance, procurement, project portfolio management, supply chain management, business analytics and enterprise performance management, and industry-specific applications software; and virtual machine instance, hardware and related support, and software and hardware management and maintenance services. In addition, the company offers customers with rights to software product upgrades and maintenance releases; patches released; and Internet access to technical content, as well as Internet and telephone access to technical support personnel. Further, it provides servers, storage, networking, virtualization software, operating systems, and management software to support various IT environments; and hardware systems support solutions, such as software updates for the software components. Additionally, the company offers consulting services, such as IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancement and upgrade; customer support services; and education services. Oracle Corporation was founded in 1977 and is headquartered in Redwood City, California.
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections. The company also focuses on using its series of proprietary lead compounds from its novel macrolide library for uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.